Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.
Although RSV causes serious pediatric respiratory disease, an effective vaccine does not exist. To capture the strengths of a live virus vaccine, we have used the murine parainfluenza virus type 1 (Sendai virus [SV]) as a xenogeneic vector to deliver the G glycoprotein of RSV. It was previously shown (J. L. Hurwitz, K. F. Soike, M. Y. Sangster, A. Portner, R. E. Sealy, D. H. Dawson, and C. Coleclough, Vaccine 15:533-540, 1997) that intranasal SV protected African green monkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced to clinical trials as a vaccine for hPIV1 (K. S. Slobod, J. L. Shenep, J. Lujan-Zilbermann, K. Allison, B. Brown, R. A. Scroggs, A. Portner, C. Coleclough, and J. L. Hurwitz, Vaccine, in press). Recombinant SV expressing RSV G glycoprotein was prepared by using reverse genetics, and intranasal inoculation of cotton rats elicited RSV-specific antibody and elicited protection from RSV challenge. RSV G-recombinant SV is thus a promising live virus vaccine candidate for RSV.
Takimoto
Toru
T
St. Jude Children's Research Hospital, 332 N. Lauderdale St., Memphis, TN 38105, USA.
Hurwitz
Julia L
JL
Coleclough
Chris
C
Prouser
Cecilia
C
Krishnamurthy
Sateesh
S
Zhan
Xiaoyan
X
Boyd
Kelli
K
Scroggs
Ruth A
RA
Brown
Brita
B
Nagai
Yoshiyuki
Y
Portner
Allen
A
Slobod
Karen S
KS
D000818:Animals; D007114:Immunization; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology*; D029082:Sendai virus / Q000235:genetics; D016205:Sigmodontinae; D014614:Vaccines, Synthetic / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology*
D022261:Respiratory Syncytial Virus Vaccines; D014614:Vaccines, Synthetic; D014764:Viral Proteins